# FDA Approves Sanofi-Aventis Biologic Drug The U.S. Food and Drug Administration has approved a new biologic drug from Sanofi-Aventis US (BLA208471), potentially strengthening the company's portfolio in a competitive therapeutic market. The approval expands Sanofi-Aventis's treatment options and could capture additional market share in its respective indication segment.